Trial · NCT04222712

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

NCT04222712, Phase 1, Phase 2, Completed, Tarsier Pharma; results first posted 2023-10-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis. Trials, record NCT04222712. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04222712

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis
NCT number: NCT04222712
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 16 participants, actual
Lead sponsor: Tarsier Pharma
Conditions: Non-infectious Anterior Uveitis
Interventions: TRS01 eye drops, TRS01 eye drops
First posted: 2020-01-10
Last updated: 2023-10-05
Results first posted: 2023-10-05

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Assessment of Both Systemic and Ocular Adverse Events	10 weeks	Number of patients experiencing Adverse Events during the study

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Assessment of Both Systemic and Ocular Adverse Events	10 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Assessment of Both Systemic and Ocular Adverse Events	TRS01 Low Dose		2		Participants
Assessment of Both Systemic and Ocular Adverse Events	TRS01 High Dose		5		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	TRS01 Low Dose	8
Overall Study	STARTED	TRS01 High Dose	8
Overall Study	COMPLETED	TRS01 Low Dose	8
Overall Study	COMPLETED	TRS01 High Dose	8
Overall Study	NOT COMPLETED	TRS01 Low Dose	0
Overall Study	NOT COMPLETED	TRS01 High Dose	0

Source ClinicalTrials.gov

Adverse events32

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anxiety	Psychiatric disorders	TRS01 Low Dose	0	8
other	Anxiety	Psychiatric disorders	TRS01 High Dose	1	8
other	Arthropod bite	Injury, poisoning and procedural complications	TRS01 Low Dose	0	8
other	Arthropod bite	Injury, poisoning and procedural complications	TRS01 High Dose	1	8
other	Arthralgia	Musculoskeletal and connective tissue disorders	TRS01 Low Dose	0	8
other	Arthralgia	Musculoskeletal and connective tissue disorders	TRS01 High Dose	1	8
other	Instillation site pain	General disorders	TRS01 Low Dose	0	8
other	Instillation site pain	General disorders	TRS01 High Dose	1	8
other	Fatigue	General disorders	TRS01 Low Dose	0	8
other	Fatigue	General disorders	TRS01 High Dose	1	8

1 to 10 of 32Source ClinicalTrials.gov

See all 32 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	TRS01 Low Dose	0	8
Total, all-cause mortality	TRS01 High Dose	0	8
Total, other adverse events	TRS01 Low Dose	2	8
Total, other adverse events	TRS01 High Dose	5	8
Total, serious adverse events	TRS01 Low Dose	0	8
Total, serious adverse events	TRS01 High Dose	0	8

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
TRS01 Low Dose vs TRS01 High Dose: deaths from any cause	Trial comparisons
TRS01 Low Dose vs TRS01 High Dose: Assessment of Both Systemic and Ocular Adverse Events	Trial comparisons
TRS01 Low Dose vs TRS01 High Dose: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04222712

GET https://conductscience.org/api/trials/v1/NCT04222712/events?page=2

API reference For AI assistants